CD99 Bone & Tissue Tumor Test | Lahalak Platform
A specialized diagnostic package for identifying high-risk bone and soft tissue tumors in youth, enabling rapid initiation of appropriate chemotherapy and targeted therapies.
Scientific name: Immunohistochemistry (IHC): CD99
This diagnostic package, based on immunohistochemistry, includes the screening of a range of markers for the diagnosis of Ewing sarcoma (EFTs) and other small round cell sarcomas. The package primarily includes testing for CD99 (MIC2), a potent cytoplasmic membrane marker strongly expressed in Ewing sarcomas, as well as essential complementary mark...
Service type
Laboratory test (Tumor Markers)
Duration
10-15 minutes
Fasting
Fasting is not required
Included Services
- CD99 (MIC2) sensitive marker testing for the initial detection of Ewing family tumors.
- High specificity marker NKX2.2 testing for nuclear confirmation of the diagnosis.
- Checking for primary exclusion markers: CD45 (LCA) to exclude lymphoma, and a neurological marker (Synaptophysin) to aid in subclassification.
- Consultation for interpretation of the overall results with a pathologist specializing in bone and soft tissue tumors, and recommendation for confirmatory molecular testing when necessary.
Medical Service Information
Conditions & Notices
- It requires the submission of a complete tissue block (paraffin block) of the bone or soft tissue biopsy specimen.
- It is necessary to attach the initial pathology report describing the tumor as a "small round blue cell" (SRBCT), along with information about the patient's age and tumor location.
- The patient does not need to fast, as the sample is tissue-based.
- Due to the high clinical importance and diagnostic urgency, the package must be completed urgently, usually within 3 to 7 working days.
Medical services you might also like
